The blood glucose monitoring devices market size is estimated to be valued at USD 14.2 billion in 2024. The market is estimated to cross a valuation of USD 22.2 billion by 2034. Market analysis suggests that the trend of choosing blood glucose monitoring devices is driven by a rise in the prevalence of diabetes and the ageing population worldwide.
Market Outlook:
Data Points | Market Insights |
---|---|
Market Value 2023 | USD 13.6 Billion |
Market Value 2024 | USD 14.2 Billion |
Market Value 2034 | USD 22.2 Billion |
CAGR 2023 to 2033 | 4.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
CAGR from 2019 to 2023 | 5.0% |
---|---|
CAGR from 2024 to 2034 | 4.9% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Countries | 2034 Value CAGR in Global Market |
---|---|
United States | 3.9% |
United Kingdom | 3.8% |
China | 4.8% |
Germany | 4.1% |
Attributes | Details |
---|---|
By Product Type | Self-Monitoring Devices |
Market Share in 2024 | 71.4% |
Attributes | Details |
---|---|
By Distribution Channel | Retail Pharmacy |
Market Share in 2024 | 38.2% |
To meet consumer demand and expand their customer base, major players are concentrating on new product launches, regulatory approvals, acquisitions, improvements in current products & technologies, and other methods to increase their business portfolio & fortify their presence.
Recent developments
Similarly, recent developments related to companies manufacturing blood glucose monitoring device products have been tracked by the team at Future Market Insights, which are available in the full report.
The global Blood Glucose Monitoring Devices market is worth USD 13.6 billion in 2022 and is set to expand 1.5X over the next ten years.
The Blood Glucose Monitoring Devices market is expected to reach USD 22.2 billion by the end of 2033, with sales revenue expected to register a 4.6% CAGR.
Growing incidences of diabetes and obesity due to the changing lifestyle and dietary habits along with the growing ageing population and increasing incidences of diabetes associated with age leading to the development of new non-invasive and quick methods of monitoring blood glucose levels are the key trends in this market.
The USA, Germany, the UK, China, and India are expected to drive demand for the Blood Glucose Monitoring Devices industry.
North America is one of the key markets for blood glucose monitoring devices, with the USA accounting for about 92.5% of the North American Blood Glucose Monitoring Devices market in the year 2022.
Demand for Blood Glucose Monitoring Devices in Europe is expected to register a growth of 4.2% over the next ten years.
The USA, Germany and the UK, are the key producers of blood glucose monitoring devices.
Abbott Laboratories, ARKRAY, Inc., Bayer AG; Medtronic plc, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Ascensia Diabetes Care, Nipro Diagnostics, Inc., Dexcom, Inc., Sanofi, Terumo Medical Corporation, Novo Nordisk, Ypsomed Holdings, Prodigy Diabetes Care, LLC, GlySens Incorporated, ACON Laboratories, Nova Biomedical, Medtronic, Dexcom, Inc., LifeScan IP Holdings, LLC, and Senseonics are the key players in the Blood Glucose Monitoring Devices industry.
1. Executive Summary 2. Market Overview 3. Brand Mapping Analysis 4. Distribution Channel Wise Key Brand Positioning 5. Consumer Buying Behavior Analysis 6. Market Trends & Dynamics 7. Value Added Insights 8. Market Background 9. Global Market Demand Analysis 2017 to 2022 and Forecast, 2023 to 2033 10. Global Market - Pricing Analysis 11. Global Market Demand (in Value or Size in USD million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Product 12.1. Self-monitoring device 12.2. Continuous blood glucose monitoring devices 13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Usage 13.1. Non-invasive 13.2. Invasive 14. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality 14.1. Standalone 14.2. Portable 15. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 15.1. Type 1 15.2. Type 2 15.3. Gestational Diabetes 16. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 16.1. Retail Pharmacy 16.2. Hospital Pharmacy 16.3. Diagnostic Centers 16.4. Online Sales 17. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 17.1. North America 17.2. Latin America 17.3. Europe 17.4. South Asia 17.5. East Asia 17.6. Oceania 17.7. Middle East & Africa 18. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 21. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 22. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 23. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 24. Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 25. Market Structure Analysis 26. Competition Analysis 26.1. Abbott Laboratories 26.2. ARKRAY, Inc. 26.3. Bayer AG; Medtronic plc 26.4. F. Hoffmann-La Roche Ltd. 26.5. Johnson & Johnson 26.6. Ascensia Diabetes Care 26.7. Nipro Diagnostics, Inc. 26.8. Dexcom, Inc. 26.9. Sanofi 26.10. Terumo Medical Corporation 26.11. Novo Nordisk 26.12. Ypsomed Holdings 26.13. Prodigy Diabetes Care, LLC 26.14. GlySens Incorporated 26.15. ACON Laboratories 26.16. Nova Biomedical 26.17. Medtronic 26.18. Dexcom, Inc. 26.19. LifeScan IP Holdings, LLC 26.20. Senseonics 27. Assumptions and Acronyms Used 28. Research Methodology
Explore Healthcare Insights
View Reports